22 Nov Burkitt’s Lymphoma: Effectivenss of Low-Intensity Therapy
MedicalResearch.com Interview with
Kieron M. Dunleavy, M.D.
Metabolism Branch
Lymphoma Therapeutics Section
Center for Cancer Research
National Cancer Institute, Bethesda, MD 20892
MedicalResearch.com: What are the main findings of the study?
Dr. Dunleavy: We found that low-intensity therapy was highly effective in Burkitt’s lymphoma and cured over 95% of patients with the disease.
MedicalResearch.com: Were any of the findings unexpected?
Dr. Dunleavy: Burkitt’s lymphoma is typically treated with very intensive chemotherapy regimens so the fact that it can be successfully treated with low-intensity therapy represents a paradigm shift.
MedicalResearch.com: What should clinicians and patients take away from your report?
Dr. Dunleavy: Low-intensity therapy (EPOCH-R based treatment) is highly effective in Burkitt’s lymphoma and associated with low toxicity compared to standard Burkitt’s lymphoma regimens.
MedicalResearch.com: What recommendations do you have for future research as a result of this study?
Dr. Dunleavy: To validate these results, we are currently studying this approach in a multi center study of Burkitt’s lymphoma and the approach is also being tested in a pediatric study.
Citation:
Low-Intensity Therapy in Adults with Burkitt’s Lymphoma
N Engl J Med 2013; 369:1915-1925November 14, 2013DOI: 10.1056/NEJMoa1308392
Last Updated on November 22, 2013 by Marie Benz MD FAAD